Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
Journal Article
Overview
publication date
- September 1, 2020
has subject area
- Aged
- Animals
- Azepines
- Benzoxazoles
- Cell Cycle Proteins - Aurora Kinase A
- Cell Line - Cell Line, Tumor
- Drug Resistance, Neoplasm
- Drug Therapy - Antineoplastic Combined Chemotherapy Protocols
- Drug Therapy, Combination - Antineoplastic Combined Chemotherapy Protocols
- Female
- Humans
- Investigative Techniques - Xenograft Model Antitumor Assays
- Male
- Mice
- Middle Aged
- Multiprotein Complexes - Mechanistic Target of Rapamycin Complex 1
- Multiprotein Complexes - Mechanistic Target of Rapamycin Complex 2
- Neoplasm Transplantation - Xenograft Model Antitumor Assays
- Neoplasms
- Protein Kinase Inhibitors
- Protein-Serine-Threonine Kinases - Aurora Kinase A
- Protein-Serine-Threonine Kinases - Mechanistic Target of Rapamycin Complex 1
- Protein-Serine-Threonine Kinases - Mechanistic Target of Rapamycin Complex 2
- Proteins - Mechanistic Target of Rapamycin Complex 1
- Proteins - Mechanistic Target of Rapamycin Complex 2
- Pyrimidines
- Therapeutics - Antineoplastic Combined Chemotherapy Protocols
- Toxicity Tests - Maximum Tolerated Dose
- Toxicological Phenomena - Maximum Tolerated Dose
- Tumor Cells, Cultured - Cell Line, Tumor
has restriction
- green
Date in CU Experts
- May 19, 2020 11:12 AM
Full Author List
- Davis SL; Ionkina AA; Bagby SM; Orth JD; Gittleman B; Marcus JM; Lam ET; Corr BR; O'Bryant CL; Glode AE
author count
- 21
citation count
- 7
published in
- Clinical Cancer Research Journal
Other Profiles
International Standard Serial Number (ISSN)
- 1078-0432
Electronic International Standard Serial Number (EISSN)
- 1557-3265
Digital Object Identifier (DOI)
Additional Document Info
start page
- 4633
end page
- 4642
volume
- 26
issue
- 17